[HTML] frontiersin.org

[HTML][HTML] Discovery of a series of 1, 2, 3-triazole-containing erlotinib derivatives with potent anti-tumor activities against non-small cell lung cancer

G Sun, L Mao, W Deng, S Xu, J Zhao, J Yang… - Frontiers in …, 2022 - frontiersin.org
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are emerging at
the vanguard of therapy for non-small-cell lung cancer (NSCLC) patients with EGFR …
被引用次数：7 相关文章

Discovery of a Series of 1, 2, 3-Triazole-Containing Erlotinib Derivatives With Potent Anti-Tumor Activities Against Non-Small Cell Lung Cancer.

G Sun, L Mao, W Deng, S Xu, J Zhao, J Yang… - Frontiers in …, 2022 - europepmc.org
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are emerging at
the vanguard of therapy for non-small-cell lung cancer (NSCLC) patients with EGFR …

Discovery of a series of 1, 2, 3-triazole-containing Erlotinib derivatives with potent anti-tumor activities against non-small cell lung cancer

G Sun, L Mao, W Deng, S Xu, J Zhao… - Frontiers in …, 2022 - ui.adsabs.harvard.edu
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are emerging at
the vanguard of therapy for non-small-cell lung cancer (NSCLC) patients with EGFR …

Discovery of a Series of 1, 2, 3-Triazole-Containing Erlotinib Derivatives With Potent Anti-Tumor Activities Against Non-Small Cell Lung Cancer

G Sun, L Mao, W Deng, S Xu, J Zhao… - Frontiers in …, 2022 - pubmed.ncbi.nlm.nih.gov
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are emerging at
the vanguard of therapy for non-small-cell lung cancer (NSCLC) patients with EGFR …
[HTML] nih.gov

[HTML][HTML] Discovery of a Series of 1, 2, 3-Triazole-Containing Erlotinib Derivatives With Potent Anti-Tumor Activities Against Non-Small Cell Lung Cancer

G Sun, L Mao, W Deng, S Xu, J Zhao, J Yang… - Frontiers in …, 2021 - ncbi.nlm.nih.gov
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are emerging at
the vanguard of therapy for non-small-cell lung cancer (NSCLC) patients with EGFR …

Discovery of a Series of 1, 2, 3-Triazole-Containing Erlotinib Derivatives With Potent Anti-Tumor Activities Against Non-Small Cell Lung Cancer.

G Sun, L Mao, W Deng, S Xu, J Zhao, J Yang… - Frontiers in …, 2022 - europepmc.org
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are emerging at
the vanguard of therapy for non-small-cell lung cancer (NSCLC) patients with EGFR …